Otsuka Unveils Phase 3 VOYXACT Results for IgA Nephropathy Treatment

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) recently announced new data from the Phase 3 VISIONARY trial demonstrating that VOYXACT (sibeprenlimab-szsi) stabilizes estimated glomerular filtration rate (eGFR) returning kidney function decline to baseline physiologic rate over two years (24 months) in adults with primary IgA nephropathy (IgAN) at risk for disease […]